Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8191 to 8205 of 8900 results

  1. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  2. Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)

    This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].

    Withdrawn guidance

  3. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  4. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  5. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Withdrawn guidance

  6. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Withdrawn guidance

  7. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Withdrawn guidance

  8. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  9. Laparoscopic surgery for hernia (TA18)

    This guidance has been replaced by NICE technology appraisal guidance 83.

    Withdrawn guidance

  10. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (TA182)

    This guidance has been replaced by NICE technology appraisal guidance 317.

    Withdrawn guidance

  11. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  12. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

    Withdrawn guidance

  13. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Withdrawn guidance

  14. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Withdrawn guidance

  15. Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) (TA224)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance